
Please join us for the latest installment of Cooley Talks Life Sciences. In this quarterly virtual series, we tap into Cooley’s unrivaled network of life sciences thought leaders to discuss key industry developments, challenges, solutions and the road ahead.
This episode explores how artificial intelligence (AI) and digital health are reshaping the life sciences industry – from accelerating research and development to transforming commercialization strategies. The esteemed panel will dive into the evolving investment landscape, spotlighting where capital is flowing, how valuations are shifting, and what companies and investors need to know when adopting AI-powered and digital therapeutic solutions.
Topics for discussion
- AI’s expanding role in life sciences: From early-stage research to clinical development and beyond, how AI is driving efficiency and innovation
- Digital therapeutics on the rise: The evolving regulatory environment and what investors need to know
- Investment trends and valuation frameworks: Where capital is flowing in AI, digital health and life sciences – and how deal structures are adapting
- Strategic partnerships and scaling: How companies and investors can collaborate to accelerate growth while mitigating risk
- IP strategy: Protecting and enforcing IP, structuring portfolios for strategic advantage, and unlocking monetization opportunities in the AI-life sciences landscape
Panelists
- Justin Butler – Partner at Eclipse Ventures
- Dan Gebremedhin, MD – Partner at Flare Capital Partners
- Sonia Nath – Partner and chair of the global life sciences and healthcare regulatory practice at Cooley
- Madhuri Roy, PhD – Partner at Cooley
- Charity Williams (moderator) – Partner at Cooley